RBC Capital analyst Shagun Singh raised the firm’s price target on Teleflex (TFX) to $135 from $120 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that Teleflex is “a show me story” in 2026 as it executes on the planned separation of certain businesses.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex price target raised to $139 from $114 at Wells Fargo
- Teleflex Announces $2.03 Billion Business Sale Agreements
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Teleflex’s Strategic Divestitures and Financial Stabilization Justify Hold Rating Amid Fair Valuation
- Teleflex Stock (TFX) Soars on a $2B Deal